Financial News
Latest News about Phase 2 Trial
Recent news which mentions Phase 2 Trial
   Vertex Unveils First Patient Results On Potential Diabetes Treatment
   
  October 18, 2021
  Tickers 
   VRTX
  
  
  From Benzinga
 
   Denali Highlights Encouraging Early Data, Update For Amyotrophic Lateral Sclerosis Program
   
  
  
  October 07, 2021
  From Benzinga
 
   Vaxart Starts Recruitment In Mid-Stage COVID-19 Oral Vaccine Trial
   
  October 06, 2021
  Tickers 
   VXRT
  
  
  From Benzinga
 
   Takeda Discontinues Two Mid-Stage Narcolepsy Trials
   
  
  
  October 06, 2021
  From Benzinga
 
   Gemini Axes Chief Scientific Officer, 20% Of Staff To Focus On Geographic Atrophy Candidate
   
  October 05, 2021
  Tickers 
   GMTX
  
  
  From Benzinga
 
   EXCLUSIVE: Annovis Bio's Parkinson's Candidate Improves Speed, Motor Function Vs Placebo
   
  October 05, 2021
  Tickers 
   ANVS
  
  
  From Benzinga
 
   Enanta To Discontinue Internal Development Of NASH Candidates
   
  October 04, 2021
  Tickers 
   ENTA
  
  
  From Benzinga
 
   Xenon Pharma Shares Jump After Epilepsy Treatment Phase 2 Data Meets Primary Endpoint
   
  October 04, 2021
  Tickers 
   XENE
  
  
  From Benzinga
 
   J&J's RSV Vaccine Candidate Shows 80% Efficacy In Older Adults
   
  October 04, 2021
  Tickers 
   JNJ
  
  
  From Benzinga
 
   Eli Lilly's Mirikizumab Maintains Symptomatic Remission for Two Years In Ulcerative Colitis Patients
   
  October 01, 2021
  Tickers 
   LLY
  
  
  From Benzinga
 
   Precigen Posts Additional Interim Data From Type 1 Diabetes Trial
   
  
  
  October 01, 2021
  From Benzinga
 From Benzinga
 
   Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations
   
  September 30, 2021
  Tickers 
   NERV
  
  
  From Benzinga
 
   AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses
   
  September 30, 2021
  Tickers 
   AIM
  
  
  From Benzinga
 
   Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail
   
  
  
  September 30, 2021
  From Benzinga
 
   Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate
   
  September 29, 2021
  Tickers 
   EDIT
  
  
  From Benzinga
 
   Adagio's COVID-19 Candidate Shows Prolonged Half-Life, Neutralization At Six Months
   
  
  
  September 29, 2021
  From Benzinga
 
   Graybug Vision Posts Six-Month Extension GB-102 Data Of Wet AMD Trial
   
  
  
  September 28, 2021
  From Benzinga
 
   Why Are I-Mab Shares Trading Higher On Tuesday?
   
  
  
  September 28, 2021
  From Benzinga
 
   Valneva, Pfizer Lyme Disease Vaccine Candidate Drops-Off After 18 Months
   
  
  
  September 28, 2021
  From Benzinga
 
   Ultragenyx Resumes Dosing Antisense Trial In Rare Neurogenetic Disorder
   
  September 27, 2021
  Tickers 
   RARE
  
  
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 

 
  
 
 
 










